Exelixis Puts '184 Back in Spotlight With "Dramatic" Prostate Cancer Results
This article was originally published in The Pink Sheet Daily
Executive Summary
In interim Phase II data, the unpartnered drug reverses bone lesions in metastatic prostate cancer patients.